Latest News

View allAccessAL amyloidosisCAR-TConferencesMPEMyelomaNewsPatient evidenceVideos

MPE announces partnership in EU consortium project CERTAINTY: advancing cancer care through virtual twins in personalised immunotherapy

MPE announces partnership with an international team, including representatives from scientific, industry, and healthcare sectors, as part of the EU-funded research project CERTAINTY, which began in December 2023. The EU consortium “CERTAINTY – A cellular immunotherapy virtual twin for personalized cancer treatment” is being funded by the European Union with almost EUR 10 million over…

Read more

ASH 2023 | Myeloma and AL amyloidosis updates

Myeloma Patients Europe (MPE) attended the 65th American Society of Hematology (ASH) Annual Meeting, the largest haematology congress, held from 9 to 12 December in San Diego (United States). MPE has interviewed haematology experts to summarise the latest myeloma and AL amyloidosis updates.   Prof. Dr. Michel Delforge, Department of Haematology, University Hospital Leuven, Belgium, explains…

Read more

EMA CHMP confirms recommendation for non-renewal of Blenrep marketing authorisation

The European Medicines Agency (the EU medicines regulator) Committee for Medicinal Products for Human Use (CHMP) has today confirmed their earlier recommendation to not renew marketing authorisation for belamaf mafadotin (Blenrep®). The confirmation follows a review of the CHMP decision, requested by the manufacturer GSK. MPE Co-Chief Executive Officer, Kate Morgan, commented: “The final recommendation…

Read more

The European Commission grants final approval for elranatamab for the treatment of relapsed or refractory myeloma

The European Commission has granted conditional marketing authorisation for elranatamab, also known as Elrexfio® marketed by the pharmaceutical company Pfizer. This follows an earlier positive recommendation from the European Medicines Agency (EMA – the EU drug licensing body) Committee for Medicinal Products for Human Use (CHMP), after which the European Commission had 60 days to…

Read more

2023: Year in Review

On behalf of the Myeloma Patients Europe (MPE) Board of Directors and staff, we extend a heartfelt thank you to our members, sponsors and stakeholders for your dedication and inspiration. This year, MPE achieved significant milestones made possible by our collective efforts, and we are thrilled to present our Year in Review 2023. We hope you’ll…

Read more

Myeloma and AL amyloidosis ASH 2023 preview

The American Society of Hematology (ASH) Annual Meeting, the world’s largest haematology conference, will take place from 9 – 12 December in San Diego, United States. It is a very exciting event for the myeloma and AL amyloidosis clinical and patient community, with all the results from the latest and most important research being presented.…

Read more
July

August 2026

September
MO
TU
WE
TH
FR
SA
SU
27
28
29
30
31
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
1
2
3
4
5
6
Events for 1st August
No Events
Events for 2nd August
No Events
Events for 3rd August
No Events
Events for 4th August
No Events
Events for 5th August
No Events
Events for 6th August
No Events
Events for 7th August
No Events
Events for 8th August
No Events
Events for 9th August
No Events
Events for 10th August
No Events
Events for 11th August
No Events
Events for 12th August
No Events
Events for 13th August
No Events
Events for 14th August
No Events
Events for 15th August
No Events
Events for 16th August
No Events
Events for 17th August
No Events
Events for 18th August
No Events
Events for 19th August
No Events
Events for 20th August
No Events
Events for 21st August
No Events
Events for 22nd August
No Events
Events for 23rd August
No Events
Events for 24th August
No Events
Events for 25th August
No Events
Events for 26th August
No Events
Events for 27th August
No Events
Events for 28th August
No Events
Events for 29th August
No Events
Events for 30th August
No Events
Events for 31st August
No Events